Landing
The ‘Unused Billion’: How Points4Purpose is Disrupting the Flatlining Loyalty Market
The loyalty industry is plagued by “sameness,” leaving billions in value dormant. Ivan Schwartz’s Points4Purpose is disrupting this flatlining market by turning rewards into a liquid currency for rent, bills, and over 1.8 million charities.
1,000km, sustainable, efficient , no onboard pilot: How ‘Gap Drone ’ is rewriting the rules of remote logistics
Can autonomous drones solve Australia’s “tyranny of distance”? GAP Drone CEO Liesl Haris thinks so. With the launch of ATLAS—an autonomous transport logistics aircraft system—the company is bypassing traditional infrastructure to deliver 50kg payloads over 1,000km. Dubbed the “Uber of airfreight,” GAP Drone is tackling the “too hard basket” of remote logistics, partnering with Australia Post to provide First Nations communities and regional hubs with reliable, low-cost access to medicine, food, and economic opportunity. By operating within current regulatory frameworks and utilising a “no-runway” launch model, GAP Drone is transforming air freight from an expensive luxury into a scalable utility.
Precision Care, Zero Clicks: Why the Future of the NDIS is Voice-First
Carelogix is solving the healthcare burnout crisis by replacing manual typing with a sophisticated AI “care co-pilot.” By reclaiming nearly half of a caregiver’s day, the platform offers a significant value inflection point for providers and investors in the trillion-dollar care economy.
The Private Equity Signal I Am Watching Very Closely
Pattern recognition in private markets is not about predicting the future. It is about reading what is already moving before the wider market notices. I spotted the same signal in life sciences 18 months before it became consensus. We are watching it happen again, this time in private equity.
Arterial Alchemy: Turning the ‘Ticking Time Bomb’ of Heart Disease into Excretable Waste
Current heart medications thin the “grease” in our blood, but Atherid Therapeutics is building the first biological clearing agent to actually scrub the pipes clean. With human trials slated for 2027, the goal is to make heart attacks a preventable and reversible condition.
Breaking the ‘Bird’s Nest’: How Amplia Therapeutics is Piercing the Shield of Pancreatic Cancer
Led by award-winning drug developer Dr. Chris Burns, Amplia Therapeutics (ASX: ATX) is taking a “one-two punch” approach to one of medicine’s deadliest challenges. By utilizing their lead asset, narmafotinib, to dismantle the protective “bird’s nest” of fibrotic tissue surrounding pancreatic tumors, Amplia has achieved a 35% interim response rate in Phase 2a trials. With FDA Fast Track status and critical survival data expected in 2026, the company is rapidly approaching a major commercial and clinical rerate.
What Active Private Market Investors Told Us They Want in 2026
We just released the 2026 Investor Survey, the most comprehensive look at what private market investors are actually thinking and prioritizing as they deploy capital this year. Key data challenges assumptions, revealing that nearly 68% of the active investor base are individuals, not institutions.
The Better Pill to Swallow: Solving the $60B Drug Delivery Problem with AI
While most biotechs hunt for new molecules, BCS2 is fixing the ones we already have. Founder Stuart Gunzburg explains how his AI-powered platform transforms “insoluble” blockbuster drugs into rapid-acting sprays and films, creating a de-risked, high-speed pathway to market for a $60 billion opportunity.
The Silent Trigger: How Biotome is Dismantling the World’s Fourth Deadliest Cancer
Biotome is transforming gastric cancer detection through precision immunology. Their flagship test Helitope uses peptide augmentation to target specific bacterial markers, delivering 10 times greater sensitivity and 95% accuracy compared to traditional diagnostic tests.
Backed By Leading Investment Groups and Family Offices
